AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05660473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaspargase
Description: Polyethylene glycol (PEG) conjugated to L-asparaginase
Study NCT05660473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Glucocorticoids
Study NCT05847218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHN-001 (one tablet 750mg)
Description: Subjects in A1 and A2 will receive 750mg RHN-001 or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
Study NCT05660473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Pyrimidine antimetabolites
Study NCT05660473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine
Description: Cell cycle-specific antitumor drug
Study NCT05660473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Glucocorticoids
Study NCT05660473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Antifolate antineoplastic drug
Study NCT05660473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Selective inhibitor of B-cell lymphoma 2 (Bcl-2)
Study NCT05847218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RHN-001 (750mg * 2 Tablets)
Description: Subjects in B1 and B2 will receive 1500mg RHN-001 (750mg tablet) or matching placebo tablets in Fasted state and Fed states respectively with 240 mL ambient temperature water.
Study NCT05474937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane Inhalation Solution
Description: Patients in inhalational group will receive Sevoflurane at 7% dial concentration in 100% O2 by an appropriately sized face mask until adequate sedation occurs as adequate jaw relaxation for the endoscope insertion and attainment of Modified Ramsay Sedation Score (MRSS) 7 (i.e., Asleep, reflex withdrawal to painful stimuli only).
Study NCT05493553 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary supplement regimen
Description: The powdered, soluble fiber-based supplement contains soluble fibers, phytosterols, plant-derived polysaccharides, flavor, maltodextrin, orange juice powder, citric acid, vitamin and mineral blend, and sweetener. This is prepared in water and consumed twice per day, prior to a meal.~The yerba mate-based supplement (containing green yerba mate leaf extract, sweeteners, and flavor) is a powdered supplement prepared in water and consumed in the morning.
Study NCT05493553 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary supplement and intermittent fasting regimen
Description: The dietary supplement regimen is the same as in Phase 1. The intermittent fasting protocol consists of a 16-hour fasting period and an 8-hour eating window.
Study NCT05839769 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Evaluation of median nerve with ultrasound
Description: ultrasound examination wrist
Study NCT05519254 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Description: Caregivers of children will be instructed to provide 1.5g of lactoferrin with 40g of unmodified rice powder daily mixed with 125 mL of porridge or other complimentary food.
Study NCT05519254 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lysozyme
Description: Caregivers of children will be instructed to provide 41.5g of Lysosure daily mixed with 125 mL of porridge or other complimentary food.
Study NCT05519254 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Lactoferrin + Lysozyme
Description: Caregivers of children will be instructed to provide 40g of Lysosure with 1.5 grams of lactoferrin daily mixed with 125 mL of porridge or other complimentary food.
Study NCT05519254 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Caregivers of children will be instructed to provide 41.5 grams of unmodified rice powder daily mixed with 125 mL of porridge or other complimentary food.
Study NCT04561479 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary Rehabilitation
Description: All exercise program will be applied during supervised session by a physiotherapist. Range of maximal heart rate will be screened by heart rate monitor during supervised session. Training group will receive upper extremity aerobic exercise training using arm ergometer at 60-80% of maximal heart rate (dyspnea perception at 3-4 level as well as fatigue perception at 5-6 level according to Modified Borg Scale). Inspiratory muscle training (Powerbreathe® Wellness-Inspiratory Muscle Trainer) at 50-60% of maximal inspiratory pressure (MIP) and progressive resistance training at 30-60% of 1 RM (using proprioceptive neuromuscular facilitation techniques (flexion, abduction, external rotation/extension, adduction, internal rotation) for upper extremity resistance training; using sandback for knee extensors) will be performed during 24 sessions (3 day/week; 8 weeks)
Study NCT04561479 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Alternative Exercises
Description: Control group will receive alternative upper extremity exercises combined with breathing exercises. Control group will perform alternative upper extremity exercises combined with breathing exercises during 3 days/week, for 8 weeks
Study NCT05773859 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: XP-DC vaccinations
Description: Autologous cross-presenting dendritic cells loaded with autologous tumor lysate and KLH
Study NCT06057350 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tumor removal
Description: Removal of incompletely removed early-stage colon cancer
Study NCT06057350 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tumor removal
Description: Removal of incompletely removed early-stage colon cancer
Study NCT06352853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skin incision in Cesarean Section by Diathermy
Description: Skin incision by diathermy
Study NCT06352853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Skin incision in Cesarean Section by Scalpel
Description: Skin incision by scalpel
Study NCT06465147 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCRI-CAR19v3
Description: Single infusion of SCRI-CAR19v3
Study NCT06171113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK4024484C
Description: Doses administrated orally with 240 mL of water.
Study NCT05698199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITI-1001
Description: ITI-1001 DNA vaccine represents a multi-antigen nucleic acid cancer immunotherapy encoding 3 CMV antigens. The vaccine is comprised of 2 DNA plasmids: 1 plasmid encoding IE-1 and pp65 antigens as a fusion protein with LAMP1. Another plasmid encodes gB antigen as a fusion protein with LAMP1.
Study NCT05513417 — intervention group
Intervention type: DEVICE
Intervention: Bloom Pod
Description: Pelvic floor program consisting of exercise performed while using the device, education and behavioural change
Study NCT05474937 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam, Ketamine and Propofol
Description: Preoxygenation with 100% O2 for 1 minute, by proper sized face mask. Patients in Ketamine -midazolam -propofol (KMP) group will receive 1-1.5 mg/kg IV ketamine and 0.05mg/kg IV Midazolam and 1mg/kg IV Propofol as induction dose then followed by incremental doses of 0.5 mg/kg IV Propofol alone for maintenance and if procedure is prolonged propofol infusion at 100 μg/kg/min is given for maintenance of sedation. Induction dose will be considered as adequate if adequate jaw relaxation for endoscope insertion and Modified Ramsay Sedation Score (MRSS) ≥7 occurs with maintenance of spontaneous respiration. Induction time will be considered as time from beginning of IV agent to achievement of MRSS ≥7. After endoscope insertion, maintenance of oxygenation by nasal cannula at flow twice the minute ventilation of the patient
Study NCT05472857 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Claudin 18.2 CAR-T
Description: treatment with anti-claudin18.2 chimeric antigen receptor T-cell infusion
Study NCT04675060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQ-B3139 capsules
Description: TQ-B3139 capsules administered 600mg orally, twice daily in 28-day cycle.
Study NCT05491278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fospropofol disodium for injection
Description: Fospropofol disodium for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
Study NCT05491278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol for injection continuous infusion to reach a RASS score of -3 to 0. Remifentanil continuous infusion of 4 to 9 ug/kg/h for. The dosage adjustment plan was determined by the attending physician. Whether to use other sedative drugs is up to the attending physician.
Study NCT05578755 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FutureU
Description: FutureU is based on the assumption that future orientation can be strengthened by increasing the extent to which people identify with their future self. People who identify more with their future self appear to be more inclined to make more altruistic choices favoring their future self and foregoing immediate gratification. The intervention provides psychoeducation and exposure to and interaction with the future self. Participants interact with a digitally aged version of themselves, i.e., their 'future self', using a smartphone application (app) or through immersive virtual reality (VR).~The app consists of three week-long modules. Participants interact with the app on a daily basis for about 5 minutes a day for 21 consecutive days.~The VR consists of three sessions, each lasting about 30 minutes. Each VR session is guided by a trained researcher.
Study NCT06005441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-514 injection
Description: Provided as a ready for use injectable CBL-514 solution
Study NCT06005441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-A1 Injection
Description: Provided as a ready for use injectable CBL-A1 solution
Study NCT06005441 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBL-A2 Injection
Description: Provided as a ready for use injectable CBL-A2 solution
Study NCT06171113 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Doses administrated orally with 240 mL of water.
Study NCT06005441 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride
Description: Sodium Chloride (0.9% NaCl) placebo for injection
Study NCT05578755 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Goal-setting
Description: In the control condition participants set goals (as in the intervention conditions), but receive no further guidance.
Study NCT06217952 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SPL84
Description: SPL84 solution for nebulization
Study NCT06217952 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution for nebulization
Study NCT05541601 — intervention group
Intervention type: OTHER
Intervention: Blood and Urine samples
Description: The samples will be used to identify a range of tests (including genetic, protein and other biomarkers), which along with the clinical data will hopefully identify those most at risk of developing HCC, and to identify HCC at the earliest possible time points.
Study NCT05488652 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time restricted eating
Description: not more than 10 hrs. eating window daily goal for 6 months
Study NCT05634421 — intervention group
Intervention type: OTHER
Intervention: E-learning
Description: The E-learning is under development at the department of Dermatology from MUMC+.
Study NCT05415826 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: slow-release dexamethasone implant
Description: The eyes with proliferative diabetic retinopathy underwent PPV with silicone oil filling with or without slow-release dexamethasone implant at the end of surgery.
Study NCT05415826 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: slow-release dexamethasone implant
Description: The eyes with proliferative diabetic retinopathy underwent PPV with silicone oil filling with or without slow-release dexamethasone implant at the end of surgery.
Study NCT06384404 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: PROMIS questionnaire
Study NCT06485492 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant an aneurysm embolization system
Description: The product uses minimally invasive interventional method to treat intracranial aneurysms approved for application. The study physician selects the appropriate size and/or shape of the aneurysm based on the size and shape of the intracranial arterioma. The aneurysm embolization system device is inserted into the arterioma through a compatible neurovascular microcatheter.
Study NCT06538168 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self-Management Education (DSME)
Description: The intervention, Diabetes Self-Management Education (DSME), involves a structured educational program including daily reminders regarding medication, and foot care, educational-led video weekly, and handouts for the management od diabetes and foot care to enhance knowledge and skills in managing diabetes and preventing complications like diabetic foot ulcers (DFUs).
Study NCT05200507 — intervention group
Intervention type: DEVICE
Intervention: High Frequency Percussive Ventilation
Description: High Frequency Percussive Ventilation will be applied for 10 minutes at an oscillation frequency of 10 Hz, superimposed to the ventilatory assistance
Study NCT04981626 — intervention group
Intervention type: OTHER
Intervention: Clinical and experimental session
Description: Psychologic profile with standardized interview and scales (see below for details: SCID, BDI, STAI, BPQ, EDE Q, Pictorial Body Image Scale (PBIS) and EDI).~Measure the stomach-brain synchrony during EEG/EGG resting state, the distribution of voluntary actions across the respiratory phase, and the distribution of saccadic eye movements across the cardiac-cycle.
Study NCT05066074 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal Radial Vascular Access
Description: Distal Radial Vascular Access
Study NCT05066074 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal Radial Vascular Access
Description: Distal Radial Vascular Access
Study NCT06531954 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus nerve stimulation
Description: Vagus nerve stimulation group: Vagus stimulation was applied bilaterally through the ear. taVNS was performed with the Vagustim device. The stimulation pulse width was 300 microseconds, the frequency was 10 Hz, and it was biphasic with a 20-minute duration. Electrodes were placed on the concha and tragus parts of the ear, and the current was increased through these electrodes until the participant felt pain.
Study NCT06531954 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breathing exercise
Description: Breathing exercise group: The content of breathing exercises was planned as thoracic expansion exercises. These exercises were applied to the lower, middle, and upper lobes in 3 sets of 3x10 (90 times breathing in one area) and lasted for an average of 20 minutes. Participants were asked to inhale as deeply as possible into the relevant area, hold their breath for 3 seconds, and then slowly exhale the entire breath.
Study NCT06037759 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac Biomarkers
Description: Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
Study NCT06037759 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lipidomics
Description: Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
Study NCT06037759 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Proteomics
Description: Blood samples will be collected at baseline (within 6 weeks of dialysis start), at 6 months post-commencement and 12 months post-commencement of haemodialysis. The blood sampling will be mid-week samples taken at the dialysis start for haemodialysis patients, with a similar approach for the PD controls. For the CKD controls, the blood samples will be scheduled around routine clinic attendance, adhering where possible to the time intervals for HD cases and PD controls.
Study NCT05504460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen-Oxygen Generator with Nebulizer, AMS-H-03
Description: Treatments in the test group will lasts for 12 months, and symptomatic treatment will be provided based on the actual symptoms of the subjects. Subjects in the test group will be required to receive inhalation for at least 4 days every 7 days with at least 3780L inhaled every 7 days (It is recommended to inhale at least 540L per day; If the flow rate is 3L/min, it is recommended that the cumulative inhalation time should be at least 3 hours per day. If the flow rate is 1.5L/min, it is recommended that the cumulative inhalation time should be at least 6 hours per day).
Study NCT05504460 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: basic treatment
Description: supportive treatment determined by the investigator based on the condition of the patients
Study NCT05504460 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: basic treatment
Description: supportive treatment determined by the investigator based on the condition of the patients
Study NCT04547972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Higher-load resistance training
Description: This intervention will have one arm and one leg of each participant training with \~80% of their one repetition maximum
Study NCT04547972 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower-load resistance training
Description: This intervention will have one arm and one leg of each participant training with \~30% of their one repetition maximum
Study NCT04864015 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mouthpiece B1(Mouthpiece MPC-ST GMDN:62534 Generic name: Endoscopic bite block, basic, reusable
Description: Use of a Mouthpiece B1 during standard EGD instead of a conventional mouthpiece
Study NCT04864015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mouthpiece B1(Mouthpiece MPC-ST GMDN:62534 Generic name: Endoscopic bite block, basic, reusable
Description: Use of a Mouthpiece B1 during standard EGD instead of a conventional mouthpiece
Study NCT04956718 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Cold Pressor Test (CPT)
Description: Cold Pressor Test (CPT): apparatus for the task is a tank of water of temperature of 4 °C (+-0.5 °C), with instruction to immerse the hand until too uncomfortable to continue. A maximum time limit per immersion of 3-5 min is applied. Quantitative measurement can then be made of pain threshold (point first perceived as painful) and tolerance time.
Study NCT04956718 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo NaCl Nasal spray
Description: placebo nasal spray containing NaCl solution
Study NCT05301166 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology Based Motivation Education Program
Description: Technology-Based Motivation Education Program consists of web-based education, motivation program and individual motivation interviews. This program will be prepared according to the Health Belief Model (HBM). It will be applied for 4 months. Participants will take a pre-test before starting the program and a post-test at the end of the program. Individual motivation interviews will be 6 sessions in total. A website will be prepared for the Technology Based Motivation Education Program. This website consists of two parts, a web-based education and motivation program for obesity. The motivation program will enable the participant to follow the program and receive motivational messages.
Study NCT05301166 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Web Based Education
Description: Students in the control group will participate in web-based educations on obesity prepared only according to the Health Belief Model in the Technology-Based Motivation Education Program. Individual interviews supporting web-based education will be held with the control group once a month.
Study NCT05499507 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: COH
Description: Incorporates two, evidence-based individual-level interventions (home blood pressure telemonitoring coupled with the interactive obesity treatment approach, that includes nutrition and physical activity text messages with tailored feedback) and an institutional-level intervention (anti-racism training of providers and staff along with patient feedback to inform respectful care).
Study NCT05499507 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: COH+
Description: Includes all components of COH plus interpersonal support for Black women by Black women (community doula care, mental health services, and lactation support).